MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral

MHRA-102342-PIP01-26

Scope of the Application

Active Substance(s)

Sepiapterin

Condition(s)

Treatment of hyperphenylalaninaemia

Pharmaceutical Form(s)

Oral powder

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

PTC Therapeutics International Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, PTC Therapeutics International Limited submitted to the licensing authority on 19/02/2026 15:22 GMT an application for a Paediatric Investigation Plan

The procedure started on 03/03/2026 17:52 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-102342-PIP01-26

Of 14/07/2026 14:45 BST

On the adopted decision for Sepiapterin (MHRA-102342-PIP01-26) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for Sepiapterin, Oral powder , ORAL USE .

This decision is addressed to PTC Therapeutics International Limited, Unit 1, 52-55 Sir John Rogerson's Quay Dublin 2,, Dublin, IRELAND, D02 NA07

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of hyperphenylalaninaemia

2.2 Indication(s) targeted by the PIP:

Treatment of hyperphenylalaninaemia (HPA) in patients with phenylketonuria (excluding primary BH4 deficiency)

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Oral powder

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of a 125 mg strength oral powder.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	3	Study 2 (PTC923-MD-003-PKU) Open-label run-in (Part 1) followed by a double-blind, randomised, placebo-controlled (Part 2) study to evaluate pharmacokinetics, safety, and efficacy of sepiapterin in children from birth to less than 18 years of age (and adults) with phenylketonuria (PKU). Study 3 (PTC923-MD-004-PKU) Open-label, uncontrolled, long-term study to evaluate long-term safety of sepiapterin in children from birth to less than 18 years of age (and adults) with phenylketonuria (PKU). Study 4 (PTC923-PKU-401) Open-label study to evaluate long-term neurocognitive outcomes in children from 1 month to less than 10 years with phenylketonuria treated with sepiapterin.
Extrapolation, Modeling & Simulation Studies	1	Study 5 (PTC923-2024-115) Modelling and simulation study to support dose finding in children from birth to less than 18 years of age with hyperphenylalaninaemia.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No

Date of completion of the paediatric investigation plan:	31/03/2033
Deferral of one or more studies contained in the paediatric investigation plan:	Yes